BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals (NYSE: KG) reported today that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s revised prescribing information for its Skelaxin® (metaxalone) product. Skelaxin® is a leading branded muscle relaxant, indicated as an adjunct therapy for the relief of discomforts associated with acute, painful musculoskeletal conditions. The new labeling includes revised “Precautions” and “Clinical Pharmacology: Pharmacokinetics” sections.
